Romosozumab vs denosumab for steroid-related bone loss: 6-year follow-up
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study follows people with steroid-induced osteoporosis who were already treated with either romosozumab or denosumab, to see how their bone density changes after 6 years. It tests if continuing denosumab keeps bones strong.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been part of the earlier phase of this study and received either romosozumab or denosumab.
- You must continue receiving denosumab injections every 6 months after the 48-month mark.
- You must be willing to have a bone density scan (DXA) at the end of 6 years.
- You cannot be taking other osteoporosis medications.
- You cannot plan to stop or reduce your steroid (prednisolone) treatment after 48 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a drug called Denosumab, which is used to treat bone loss, can also help improve muscle strength and mass in older adults who have both osteoporosis and sarcopenia. If you qualify, you would receive the drug and be monitored over time to see if it helps your bones and muscles.
This trial compares two osteoporosis drugs (romosozumab and denosumab) given alone or together to see which works better for improving bone density. It may help if you are a postmenopausal woman with osteoporosis and have not taken strong bone medications recently.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This study looks at what medicine works best for women who have finished a 1-year course of a strong bone-building drug (romosozumab or teriparatide) for severe osteoporosis. The goal is to find a good follow-up treatment to keep bones strong and prevent fractures.
This study tests whether a combination of two medications, romosozumab and denosumab, can improve bone strength better than standard care for women after menopause who have osteoporosis and have had multiple fractures. The goal is to see if this combined approach reduces the risk of future breaks.
This study compares two treatment plans for women with osteoporosis to see which one improves hip bone density more. Participants will either get two medications in sequence (romosozumab followed by denosumab) or one medication (zoledronic acid), both given as injections or infusions. The goal is to find a treatment that reduces fracture risk.
Hear when a new Glucocorticoid-Associated Osteopenia and Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.